"Alemtuzumab" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An anti-CD52 ANTIGEN monoclonal antibody used for the treatment of certain types of CD52-positive lymphomas (e.g., CHRONIC LYMPHOCYTIC LEUKEMIA; CUTANEOUS T-CELL LYMPHOMA; and T-CELL LYMPHOMA). Its mode of actions include ANTIBODY-DEPENDENT CELL CYTOTOXICITY.
| Descriptor ID |
D000074323
|
| MeSH Number(s) |
D12.776.124.486.485.114.224.060.313 D12.776.124.790.651.114.224.060.375 D12.776.377.715.548.114.224.200.375
|
| Concept/Terms |
Campath 1H- Campath 1H
- Monoclonal Antibody Campath-1H
- Antibody Campath-1H, Monoclonal
- Campath-1H, Monoclonal Antibody
- Monoclonal Antibody Campath 1H
- Campath-1H
- Campath1H
Campath 1G- Campath 1G
- Campath-1-G
- Campath 1 G
- Campath1G
- Campath-1G
|
Below are MeSH descriptors whose meaning is more general than "Alemtuzumab".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Blood Proteins [D12.776.124]
- Immunoproteins [D12.776.124.486]
- Immunoglobulins [D12.776.124.486.485]
- Antibodies [D12.776.124.486.485.114]
- Antibodies, Monoclonal [D12.776.124.486.485.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.486.485.114.224.060]
- Alemtuzumab [D12.776.124.486.485.114.224.060.313]
- Serum Globulins [D12.776.124.790]
- Immunoglobulins [D12.776.124.790.651]
- Antibodies [D12.776.124.790.651.114]
- Antibodies, Monoclonal [D12.776.124.790.651.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.790.651.114.224.060]
- Alemtuzumab [D12.776.124.790.651.114.224.060.375]
- Globulins [D12.776.377]
- Serum Globulins [D12.776.377.715]
- Immunoglobulins [D12.776.377.715.548]
- Antibodies [D12.776.377.715.548.114]
- Antibodies, Monoclonal [D12.776.377.715.548.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.377.715.548.114.224.200]
- Alemtuzumab [D12.776.377.715.548.114.224.200.375]
Below are MeSH descriptors whose meaning is more specific than "Alemtuzumab".
This graph shows the total number of publications written about "Alemtuzumab" by people in this website by year, and whether "Alemtuzumab" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2007 | 0 | 2 | 2 |
| 2009 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2015 | 0 | 2 | 2 |
| 2017 | 0 | 1 | 1 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Alemtuzumab" by people in Profiles.
-
Santos AH, Leghrouz MA, Bueno EP, Andreoni KA. Impact of antibody induction on the outcomes of new onset diabetes after kidney transplantation: a registry analysis. Int Urol Nephrol. 2022 Mar; 54(3):637-646.
-
Koyawala N, Silber JH, Rosenbaum PR, Wang W, Hill AS, Reiter JG, Niknam BA, Even-Shoshan O, Bloom RD, Sawinski D, Nazarian S, Trofe-Clark J, Lim MA, Schold JD, Reese PP. Comparing Outcomes between Antibody Induction Therapies in Kidney Transplantation. J Am Soc Nephrol. 2017 Jul; 28(7):2188-2200.
-
Patel K, Parmar S, Shah S, Shore T, Gergis U, Mayer S, van Besien K. Comparison of Subcutaneous versus Intravenous Alemtuzumab for Graft-versus-Host Disease Prophylaxis with Fludarabine/Melphalan-Based Conditioning in Matched Unrelated Donor Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2016 Mar; 22(3):456-61.
-
Marsh RA, Rao MB, Gefen A, Bellman D, Mehta PA, Khandelwal P, Chandra S, Jodele S, Myers KC, Grimley M, Dandoy C, El-Bietar J, Kumar AR, Leemhuis T, Zhang K, Bleesing JJ, Jordan MB, Filipovich AH, Davies SM. Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab Regimen. Biol Blood Marrow Transplant. 2015 Aug; 21(8):1460-70.
-
Zhang X, Tao Y, Chopra M, Ahn M, Marcus KL, Choudhary N, Zhu H, Markovic-Plese S. Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis. J Immunol. 2013 Dec 15; 191(12):5867-74.
-
Ekdawi NS, Pulido JS, Itty S, Marler RJ, Herman DC, Hardwig P, Mohney BG, Valyi-Nagy T, Shukla D. Intravitreal alemtuzumab penetrates full-thickness retina in rabbit eyes. Retina. 2009 Nov-Dec; 29(10):1532-4.
-
Alinari L, Geskin L, Grady T, Baiocchi RA, Bechtel MA, Porcu P. Subcutaneous alemtuzumab for Sézary Syndrome in the very elderly. Leuk Res. 2008 Aug; 32(8):1299-303.
-
Eisen HJ. Immunosuppression on the horizon. Heart Fail Clin. 2007 Jan; 3(1):43-9.
-
Varadi G, Svirsky O, Nagler A. Successful major surgical recovery of a patient following haploidentical stem cell transplantation for chronic myeloid leukemia in blast crisis and aspergillosis. Acta Haematol. 2002; 108(1):29-32.